Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy.

Expert Opinion on Biological Therapy
M GalluzzoK Peris

Abstract

Background: Information is limited from real-life studies evaluating the efficacy and safety of brodalumab.Research design and methods: In this real-life study, we retrospectively examined a database of 90 patients with moderate-to-severe psoriasis treated with brodalumab (210 mg, s.c.) and followed for 1 year. Disease severity and treatment response were assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 24, 36, and 48 weeks. Predictors of a PASI response were evaluated by logistic regression.Results: After 48 weeks, 92.2% of patients (mean age 50.2 ± 15 years) treated with brodalumab achieved a PASI score of <3. PASI score decreased from 17.4 ± 10.3 at baseline to 1.7 ± 3.9 and 1.4 ± 3.7 at 12 and 24 weeks, and PASI 75, 90, and 100 response was achieved in 87.3%, 81.8%, and 72.7% of patients, respectively, at 48 weeks.Univariate regression revealed that previous exposure to anti-IL17A treatment was associated with poorer PASI response between 36 and 48 weeks. In difficult-to-treat cases previously having failed with other biologics, brodalumab significantly improved outcome, leading to complete remission.Conclusion: Brodalumab was observed to be effective and safe in patients with moderate-t...Continue Reading

References

Dec 14, 2005·American Journal of Clinical Dermatology·Alexa B KimballYing Wu
Jun 7, 2008·Current Medical Research and Opinion·Kim A PappKnut M Wittkowski
Sep 24, 2008·Dermatology : International Journal for Clinical and Investigative Dermatology·Luigi NaldiRosanna Cuscito
Sep 28, 2012·The Journal of Investigative Dermatology·Rosa ParisiUNKNOWN Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team
Jul 10, 2014·The New England Journal of Medicine·Richard G LangleyUNKNOWN FIXTURE Study Group
Oct 1, 2015·The New England Journal of Medicine·Mark LebwohlAjay Nirula
Jan 13, 2016·Postȩpy dermatologii i alergologii·Magdalena Czarnecka-OperaczDorota Jenerowicz
Jul 28, 2016·The Journal of Investigative Dermatology·Xianying XingJohann E Gudjonsson
Oct 28, 2016·The Journal of Dermatological Treatment·M GalluzzoK Peris
Mar 1, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·P GisondiG Girolomoni
Jun 7, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·M Masson RegnaultC Paul
Dec 20, 2017·Dermatology : International Journal for Clinical and Investigative Dermatology·Girish S NaikChristina Ellervik
Jun 29, 2018·Journal of the European Academy of Dermatology and Venereology : JEADV·M Munera-CamposJ M Carrascosa
Sep 27, 2018·The Journal of Dermatological Treatment·M GalluzzoM Talamonti
Feb 8, 2019·The British Journal of Dermatology·A MouradR Gniadecki
Feb 16, 2019·The British Journal of Dermatology·M NapolitanoC Patruno
Mar 27, 2019·International Journal of Molecular Sciences·Adriana Rendon, Knut Schäkel
Apr 27, 2019·Drugs in Context·Amy C Foulkes, Richard B Warren
May 13, 2019·Journal of the American Academy of Dermatology·Grace KimmelMark Lebwohl
Aug 3, 2019·Clinical, Cosmetic and Investigational Dermatology·Andreas PinterSebastian Zimmer
Aug 30, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·A EgebergL Mallbris
Oct 24, 2019·Expert Opinion on Biological Therapy·M GalluzzoM Talamonti
Feb 6, 2020·JAMA Dermatology·April W ArmstrongMatthias Augustin
Apr 7, 2020·The Journal of Dermatological Treatment·Boni ElewskiAbby Jacobson
Apr 15, 2020·Dermatologic Therapy·Paola FacherisAntonio Costanzo
May 29, 2020·Expert Opinion on Biological Therapy·Paolo Gisondi, Giampiero Girolomoni
May 30, 2020·BMJ : British Medical Journal·Rosa ParisiUNKNOWN Global Psoriasis Atlas
Jun 4, 2020·Postȩpy dermatologii i alergologii·Anna KisielnickaRoman J Nowicki
Sep 12, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·M C FargnoliUNKNOWN BRILLIANT Working Group
Dec 19, 2020·Dermatology and Therapy·Mark LebwohlAbby Jacobson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.